CHST7 and cancer: Another methylation study from Bi et al. using 432 primary CRC patients and 434 cancer-free controls reported that CHST7 methylation in white blood cells is positively associated with CRC risk, especially in females (OR = 7.704, 95% CI 4.222–14.058; p < 0.001) versus males (OR = 1.810, 95% CI 0.782–4.187; p = 0.157), and may potentially serve as a blood-based predictive biomarker for CRC risk [16].